Close
Home - Press releases - ORPHELIA Pharma and Ethypharm sign a licensing agreement for the development and marketing of Kigabeq® in China

Do you have
any question?

Contact us
19/01/2021

ORPHELIA Pharma and Ethypharm sign a licensing agreement for the development and marketing of Kigabeq® in China

Saint-Cloud and Paris – January 19, 2021 – Ethypharm and ORPHELIA Pharma announce today the signature of an exclusive agreement for the development, registration and marketing in the People’s Republic of China of Kigabeq® (vigabatrin) indicated for the first-line treatment of infantile spasms (West syndrome).

Press release

Media enquiries

Please provide a valid state.
Please provide a valid state.
Please provide a valid state.
(+)
Please provide a valid state.
Please provide a valid state.
Please provide a valid state.
*All fields must be filled in

Thank you for your message!
We will examine it with utmost attention and get back to you shortly.